Does torcetrapib reduce the progression of atherosclerotic disease?

摘要

Development of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib was suspended in December 2006 because of safety concerns. This agent had previously been shown to have a beneficial effect on HDL cholesterol levels, but its efficacy in reducing the progression of atherosclerosis remains uncertain.